Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
May 262018
 

The potential of Imetelstat has caused much speculation (e.g., https://seekingalpha.com/instablog/3163201-medtechbio/5164810-upcoming-catalysts-can-launch-geron-15-per-share; obtained on 5-26-2018).

There is currently much research being done on imtelestat that has advanced into phase three status (see https://clinicaltrials.gov/ct2/show/NCT02598661?term=imetelstat&rank=4; obtained on 5-27-18).

The Author is a current shareholder of Geron which supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

 

The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

Louis DeCola, Jr.  © 2018                                    The Hygiology Post ®